Cargando…

Serum Calcification Propensity Represents a Good Biomarker of Vascular Calcification: A Systematic Review

Vascular calcification contributes to cardiovascular morbidity and mortality. A recently developed serum calcification propensity assay is based on the half-transformation time (T50) from primary calciprotein particles (CPPs) to secondary CPPs, reflecting the serum’s endogenous capacity to prevent c...

Descripción completa

Detalles Bibliográficos
Autores principales: Pluquet, Maxime, Kamel, Said, Choukroun, Gabriel, Liabeuf, Sophie, Laville, Solène M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501050/
https://www.ncbi.nlm.nih.gov/pubmed/36136575
http://dx.doi.org/10.3390/toxins14090637
_version_ 1784795375510487040
author Pluquet, Maxime
Kamel, Said
Choukroun, Gabriel
Liabeuf, Sophie
Laville, Solène M.
author_facet Pluquet, Maxime
Kamel, Said
Choukroun, Gabriel
Liabeuf, Sophie
Laville, Solène M.
author_sort Pluquet, Maxime
collection PubMed
description Vascular calcification contributes to cardiovascular morbidity and mortality. A recently developed serum calcification propensity assay is based on the half-transformation time (T50) from primary calciprotein particles (CPPs) to secondary CPPs, reflecting the serum’s endogenous capacity to prevent calcium phosphate precipitation. We sought to identify and review the results of all published studies since the development of the T50-test by Pasch et al. in 2012 (whether performed in vitro, in animals or in the clinic) of serum calcification propensity. To this end, we searched PubMed, Elsevier EMBASE, the Cochrane Library and Google Scholar databases from 2012 onwards. At the end of the selection process, 57 studies were analyzed with regard to the study design, sample size, characteristics of the study population, the intervention and the main results concerning T50. In patients with primary aldosteronism, T50 is associated with the extent of vascular calcification in the abdominal aorta. In chronic kidney disease (CKD), T50 is associated with the severity and progression of coronary artery calcification. T50 is also associated with cardiovascular events and all-cause mortality in CKD patients, patients on dialysis and kidney transplant recipients and with cardiovascular mortality in patients on dialysis, kidney transplant recipients, patients with ischemic heart failure and reduced ejection fraction, and in the general population. Switching from acetate-acidified dialysate to citrate-acidified dialysate led to a longer T50, as did a higher dialysate magnesium concentration. Oral administration of magnesium (in CKD patients), phosphate binders, etelcalcetide and spironolactone (in hemodialysis patients) was associated with a lower serum calcification propensity. Serum calcification propensity is an overall marker of calcification associated with hard outcomes but is currently used in research projects only. This assay might be a valuable tool for screening serum calcification propensity in at-risk populations (such as CKD patients and hemodialyzed patients) and, in particular, for monitoring changes over time in T50.
format Online
Article
Text
id pubmed-9501050
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95010502022-09-24 Serum Calcification Propensity Represents a Good Biomarker of Vascular Calcification: A Systematic Review Pluquet, Maxime Kamel, Said Choukroun, Gabriel Liabeuf, Sophie Laville, Solène M. Toxins (Basel) Systematic Review Vascular calcification contributes to cardiovascular morbidity and mortality. A recently developed serum calcification propensity assay is based on the half-transformation time (T50) from primary calciprotein particles (CPPs) to secondary CPPs, reflecting the serum’s endogenous capacity to prevent calcium phosphate precipitation. We sought to identify and review the results of all published studies since the development of the T50-test by Pasch et al. in 2012 (whether performed in vitro, in animals or in the clinic) of serum calcification propensity. To this end, we searched PubMed, Elsevier EMBASE, the Cochrane Library and Google Scholar databases from 2012 onwards. At the end of the selection process, 57 studies were analyzed with regard to the study design, sample size, characteristics of the study population, the intervention and the main results concerning T50. In patients with primary aldosteronism, T50 is associated with the extent of vascular calcification in the abdominal aorta. In chronic kidney disease (CKD), T50 is associated with the severity and progression of coronary artery calcification. T50 is also associated with cardiovascular events and all-cause mortality in CKD patients, patients on dialysis and kidney transplant recipients and with cardiovascular mortality in patients on dialysis, kidney transplant recipients, patients with ischemic heart failure and reduced ejection fraction, and in the general population. Switching from acetate-acidified dialysate to citrate-acidified dialysate led to a longer T50, as did a higher dialysate magnesium concentration. Oral administration of magnesium (in CKD patients), phosphate binders, etelcalcetide and spironolactone (in hemodialysis patients) was associated with a lower serum calcification propensity. Serum calcification propensity is an overall marker of calcification associated with hard outcomes but is currently used in research projects only. This assay might be a valuable tool for screening serum calcification propensity in at-risk populations (such as CKD patients and hemodialyzed patients) and, in particular, for monitoring changes over time in T50. MDPI 2022-09-15 /pmc/articles/PMC9501050/ /pubmed/36136575 http://dx.doi.org/10.3390/toxins14090637 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Pluquet, Maxime
Kamel, Said
Choukroun, Gabriel
Liabeuf, Sophie
Laville, Solène M.
Serum Calcification Propensity Represents a Good Biomarker of Vascular Calcification: A Systematic Review
title Serum Calcification Propensity Represents a Good Biomarker of Vascular Calcification: A Systematic Review
title_full Serum Calcification Propensity Represents a Good Biomarker of Vascular Calcification: A Systematic Review
title_fullStr Serum Calcification Propensity Represents a Good Biomarker of Vascular Calcification: A Systematic Review
title_full_unstemmed Serum Calcification Propensity Represents a Good Biomarker of Vascular Calcification: A Systematic Review
title_short Serum Calcification Propensity Represents a Good Biomarker of Vascular Calcification: A Systematic Review
title_sort serum calcification propensity represents a good biomarker of vascular calcification: a systematic review
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501050/
https://www.ncbi.nlm.nih.gov/pubmed/36136575
http://dx.doi.org/10.3390/toxins14090637
work_keys_str_mv AT pluquetmaxime serumcalcificationpropensityrepresentsagoodbiomarkerofvascularcalcificationasystematicreview
AT kamelsaid serumcalcificationpropensityrepresentsagoodbiomarkerofvascularcalcificationasystematicreview
AT choukroungabriel serumcalcificationpropensityrepresentsagoodbiomarkerofvascularcalcificationasystematicreview
AT liabeufsophie serumcalcificationpropensityrepresentsagoodbiomarkerofvascularcalcificationasystematicreview
AT lavillesolenem serumcalcificationpropensityrepresentsagoodbiomarkerofvascularcalcificationasystematicreview